Optibiotix Health Share Discussion Threads

[parob] 13/12/2016 07:43

A great interview to listen to. They are in discussions with the same MN for their sugars and cholesterol technology/products.

[sukithedog] 13/12/2016 07:34

Listen so positive

INTERVIEWToday 07:26CEO Stephen OHara talks about its agreement with the multinational and provides an update on other potential commercial progress in this interview:

[john henry] 13/12/2016 07:34

Well the one code on Friday proved correct.

[woodaldo] 13/12/2016 07:31

Cracking news - what I love about this its with slimbiome and we just were thinking GoFigure and possibly slimfast. This is an unexpected bonus. It just again shows how much demand there will be for the opti range - the fact that the ugly sibling of slimbiome is already looking so successful just makes me excited about the deals that will happen with the others. Also wouldn't be surprised if this has happened off the back of GoFigures relative success - just proves again I think we have a great director in SOH.

[judijudi] 13/12/2016 07:29

Good news
Just wish they would put a bit more meat on the bone with these announcements
Figures,%'s, earnings etc etc

[f3rdinand] 13/12/2016 07:23

I always considered slimbiome to be the weakest arm...might have to rethink! Excellent news and loads mor to come over the next few months!

[john henry] 13/12/2016 07:20

Excellent news, imho there will be a deal with a MN to launch into the North American market very soon.

[someuwin] 13/12/2016 07:10

Excellent!

[tidy 2] 13/12/2016 07:09

Asians tend to be obese don't they !!

[whl2] 13/12/2016 07:06

Wasn't expecting that before Christmas - apologies to other long term holders

[larva] 13/12/2016 07:05

Another useless non announcement

[primal123] 13/12/2016 07:04

Joint Product Agreement with multinationalOptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that it has entered into a joint development agreement (the "Agreement") with a multinational. The Agreement allows for the development of food and Over The Counter ("OTC") products containing OptiBiotix's SlimBiome(R) technology for the Asian market.The multinational is a major supplier of nutritional solutions to the food, beverage, nutraceutical and pharmaceutical industries within Asia, and increasingly across global markets.The aim of the Agreement is to develop weight management products containing SlimBiome(R) technology in a range of foods and OTC products which, if successful, will be launched into the Asian market in the second half of 2017.The Company requires its identity and commercial details to remain confidential and no further details can be disclosed at this time.Discussions are ongoing and it is hoped a further announcement can be made in due course.Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of this Agreement with a multinational which creates the opportunity to launch products containing OptiBiotix's SlimBiome(R) into the Asian market next year. The multinational is a leading supplier of food ingredients with many well-known and respected brands and a multibillion dollar turnover. With India (30m) and China (46m) ranked second and third in having the highest number of overweight people in the world we hope that OptiBiotix's strong science base together with our partner's local knowledge, reputation, and sales and distribution capability will bring the benefits of SlimBiome(R) technology to a wider audience."

[judijudi] 13/12/2016 07:03

MN deal :)

[alphapig] 12/12/2016 17:38

"They can also cause nerve damage, and memory loss, because they reduce cholesterol" - I, as a layman, always thought reducing cholesterol was a healthy eating target?

[monkeywench1] 12/12/2016 13:54

Yes but you will have a long wait.

[mouse20] 12/12/2016 13:49

Yet another article in the telegraph today questioning the safety of statins.

Small extract below

"Besides the apparent benefit of statins, they appear to have a number of other effects,” says Uffe Ravnskov , a Danish physician who runs the International Network of Cholesterol Sceptics, a network for doctors and scientists. “Most commonly, statins can cause muscular weakness, or dystrophy, as well as diabetes and cancer. They can also cause nerve damage, and memory loss, because they reduce cholesterol, which is vital to brain function. These symptoms affect large numbers of patients, but people go on taking them because they’re too frightened of doctors to stop.”


Come spring and with a fair wind (and hopefully on a global scale), folks can start to reduce their reliance on statins. Then you are talking TW's telephone numbers. But the market has not yet cottoned on to this. Or don't believe it will be on such a scale. Time will tell.

[westmoreland lad] 12/12/2016 13:14

Very wise Curry !

[currypasty] 12/12/2016 13:02

buying at 63p today

[elrico] 10/12/2016 18:40

Given OPTI bought a controlling interest in UoM IP for skin care, etc, I can only ASSUME Cath O work is on said OPTI IP now - nothing else makes sense to me at any rate.

[whl2] 10/12/2016 18:26

Roll on 2017!

[john henry] 10/12/2016 18:05

Seems pretty obvious to me that J&J is one of the MN that will be involved with Skinbiotix. Agree F3 I think they will take a stake in the demerger company.

[f3rdinand] 10/12/2016 17:25

Yeah that's what I read too Elrico! Just wondering if she is working with them separately to OPTI or collaboratively! I'm personally expecting J&J to take a stake in Skinbiotix when it demerges! That should focus some minds!

[elrico] 10/12/2016 15:46

Johnson & Johnson Innovation team up with Manchester scientists Since 19 Jun 2014
As part of a strategy to explore the emerging science around the human microbiome and its impact across several areas of health and disease, Johnson & Johnson Consumer & Personal Products Worldwide and Johnson & Johnson Innovation have established a collaboration with scientists from The University of Manchester.
The collaboration will explore potential applications of probiotic extracts for prevention and treatment of skin, oral, and respiratory conditions.
Dr Catherine O’Neill, from the University’s Institute of Inflammation and Repair, and Dr Andrew McBain, from Manchester Pharmacy School, will lead on the research project with Johnson & Johnson Innovation.

Dr O’Neill said: “It’s exciting to be working with such a massive global player who we hope will really help us to develop products which will bring benefits to patients.

“This collaboration will help us co-develop a piece of technology established here in Manchester which uses probiotics – or friendly bacteria - on the skin and hopefully take this to market.”
The agreement underscores the approach Johnson & Johnson Innovation is taking to establish scientific collaborations in areas that span its pharmaceutical, medical device and diagnostics and consumer businesses.